Form 4 for INSM INSMED Inc
Accepted 2026-04-08 16:41:22 ET · period of report 2026-04-06 · accession 0001402051-26-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-08 16:41 | 2026-04-06 | INSM | Lewis William | COB, CEO, Dir | M - OptEx | $24.94 | +10.7K | 311.9K | +4% | +$266.8K |
| DMT | 2026-04-08 16:41 | 2026-04-06 | INSM | Lewis William | COB, CEO, Dir | S - Sale+OE | $163.22 | -10.7K | 301.2K | -3% | -$1.75M |
| DMT | 2026-04-08 16:41 | 2026-04-06 | INSM | Lewis William | COB, CEO, Dir | M - OptEx | $0.00 | -10.7K | 31.1K | -26% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-06 | M | A | 6,259 | $30.46 | 307,444 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2026-04-06 | M | A | 4,440 | $17.16 | 311,884 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 3 | Common | Common Stock | 2026-04-06 | S | D | 787 | $161.73 | 311,097 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F2) This is the weighted average sales price representing 787 shares sold at prices ranging from $161.65 to $162.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Common | Common Stock | 2026-04-06 | S | D | 8,478 | $163.23 | 302,619 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) This is the weighted average sales price representing 8,478 shares sold at prices ranging from $162.66 to $163.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 5 | Common | Common Stock | 2026-04-06 | S | D | 1,434 | $164.01 | 301,185 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) This is the weighted average sales price representing 1,434 shares sold at prices ranging from $163.66 to $164.36 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 6 | Derivative | Stock Option (right to buy) | 2026-04-06 | M | D | 6,259 | $0.00 | 43,814 | D | $30.46 · — to 2028-01-04 | 6,259 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F5) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 7 | Derivative | Stock Option (right to buy) | 2026-04-06 | M | D | 4,440 | $0.00 | 31,080 | D | $17.16 · — to 2027-05-17 | 4,440 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F5) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |